Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world.
In a study published in Science Immunology, researchers have shown that natural killer cells (NK cells), which are a fundamental part of the body’s immune system, can recognise many different viruses including global pathogens such as Zika, dengue and Hepatitis C viruses, through a single receptor called KIR2DS2.
Lead researcher Salim Khakoo, Professor of Hepatology, said the findings are very exciting and could change the way viruses are targeted by vaccines but warned that the research is still at an early stage, and animal studies/clinical trials will be needed to test the findings.
Vaccines work by stimulating the immune response to the coat of proteins on the virus enabling the body to fight off the virus and recognise it in the future. However, the viruses are able to change their coat proteins, helping the virus to evade the antibodies, meaning some viruses can be very hard to vaccinate against.
The Southampton team have shown that this NK cell receptor is able to target a non-variable part of the virus called the NS3 helicase protein, which is essential in making the virus work properly. Unlike other proteins, the NS3 helicase protein does not change, which allows the immune system to grab hold of it and let the NK cells deal with the threat.
Professor Khakoo said: “The NS3 helicase protein could be the key in unlocking the defence of lethal viruses that affect so many people around the world. It is very exciting to discover that other viruses similar to Hepatitis C, such as Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus and in fact all flaviviruses, contain a region within their NS3 helicase proteins that is recognised by exactly the same KIR2DS2 receptor. We believe that by targeting this NS3 helicase region, we could make a new type of vaccine based upon natural killer cells, which can be used to help protect people from these infections.”
The study, which was funded by the Wellcome Trust and the Medical Research Council, analysed DNA from more than 300 patients exposed to the Hepatitis C virus, which showed that the KIR2DS2 receptor was associated with successfully clearing the virus. The team then identified that the immune system targeted the NS3 helicase protein of this using the receptor and found that it prevented the virus multiplying.
They went on to demonstrate that this same mechanism icould be important for many different viruses for example the Zika and dengue viruses, which also contain a region within their NS3 helicase protein that is recognised by the KIR2DS2 receptor.
The researchers now need to determine whether these KIR2DS2+ NK cells are protective during acute flaviviral infections, and are hoping to develop a vaccine that targets natural killer cells. They believe that a similar process could be used to target cancer.
Professor Khakoo added: “Cancer treatments that use the body’s own immune system are becoming more common. Our findings present a completely new strategy for virus therapeutics which could be easily translated into the field of cancer. The next few years are going to be very exciting in this field.”
The Latest on: Vaccine for viruses
- The Startlingly High Cost of the ‘Free’ Flu Shoton November 19, 2019 at 7:54 pm
In the Byzantine world of health care pricing, most people wouldn’t expect that the ubiquitous flu shot could be a prime example of how the system’s lack of transparency can lead to disparate costs.
- Michael Wiblishauser: Get your flu vaccineon November 19, 2019 at 7:19 pm
There are several preventive measures you can take in order to prevent contracting the flu. One of the most well-known of the preventive measures is the influenza vaccine (flu vaccine). This vaccine ...
- Doctors offer free flu shots for migrants; CBP all but certain to say ‘no’on November 19, 2019 at 3:13 pm
“We implore you to allow our volunteer physicians to hold our requested influenza vaccination clinic,” the doctors wrote. NBC News first reported the letter. In the 2018-2019 flu season, at least ...
- After child deaths, doctors pressure Border Patrol to let them administer flu vaccineson November 19, 2019 at 2:17 pm
“It’s putting people in a dangerous situation and increasing their risks of getting any disease, including the flu,” she said, and although migrants can get vaccinated later on, “the vaccination’s not ...
- Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Planson November 18, 2019 at 4:27 pm
The global market for vaccines against chikungunya is estimated at up to €500 million annually 8. VLA1553 is based on an infectious clone (CHIKV LR2006-OPY1) attenuated by deleting a major part of the ...
- New Study: HPV Vaccine Is Safe For Kids In Preventing Certain Cancerson November 18, 2019 at 9:08 am
Only about half of today’s adolescents are completing the HPV vaccine, which can prevent cervical and head and neck cancers. HPV is very common, with about 14 million people becoming infected with the ...
- Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trialon November 18, 2019 at 6:22 am
JERUSALEM, Nov. 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial ...
- Ebola Virus Vaccine Approved Worldwide, Saves Hundreds Of Thousands Of Liveson November 18, 2019 at 3:40 am
This came to light as the health body verified that the treatment is safe for use worldwide. This made it the first Ebola vaccine certified to protect thousands of individuals who are 18 years old or ...
- A super-vaccine for the flu is being marketed to people 65 and older. Is it legit or a scam?on November 15, 2019 at 5:12 am
According to the Centers for Disease Control and Prevention, about 70%-80% of seasonal flu-related deaths occur in this age group. The regular flu vaccine just won't cut it, some doctors say. James ...
- Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccineon November 14, 2019 at 3:10 am
Here, we sought to optimize the Pfs47 vaccine to elicit higher titers of high-affinity antibodies, capable of inducing strong TRA at a lower concentration. We report the development and evaluation of ...
via Google News and Bing News